Swedish biotech company BioInvent International AB (STO:BINV) announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its first-in-class anti-TNFR2 antibody BI-1808, in combination with pembrolizumab, for the treatment of ovarian cancer.
Interim Phase 2a data presented at ASCO 2026 showed BI-1808 plus pembrolizumab achieved a 24% confirmed overall response rate and a 56% disease control rate in heavily pretreated patients with advanced platinum-resistant ovarian cancer.
The company said the combination demonstrated durable benefit across high-grade serous and clear cell subtypes, with several responses ongoing beyond 10 months and a preliminary median progression-free survival of 10.3 months.
Cohort expansion is underway with a focus on high-grade serous and clear cell ovarian cancer, and another data readout is expected in the second half of 2026.
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART